<DOC>
	<DOCNO>NCT01232361</DOCNO>
	<brief_summary>The main purpose study find stimulant medication ( methylphenidate amphetamine/ dextroamphetamine ) treatment Attention Deficit Hyperactivity Disorder ( ADHD ) process HIV-1 infect HIV-uninfected child adolescent .</brief_summary>
	<brief_title>IMPAACT P1080 : Psychiatric Antiretroviral Medication Concentrations HIV-infected Uninfected Children Adolescents</brief_title>
	<detailed_description>P1080 pilot population pharmacokinetic study HIV-1 infect uninfected child adolescent take methylphenidate amphetamine/ dextroamphetamine treatment ADHD . Prescribing various psychiatric medication combination antiretroviral regimen standard clinical practice occur without adequate evidence regard benefit risk . The goal study determine plasma concentration psychiatric antiretroviral medication child adolescent . Psychiatric medication dose requirement exposure HIV-1 infected subject compare see uninfected child adolescent , antiretroviral exposure compare publish study child adolescent .</detailed_description>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Inclusion Criteria HIV1 Infected Subjects Children adolescents age ≥6 &lt; 25 year entry . Documented HIV1 infection define positive test result obtain 2 different sample . Tests may include two type OR two different type test list , long positive test result obtain 2 different sample : HIV1 DNA PCR HIV1 culture HIV1 RNA PCR &gt; 5,000 copies/mL HIV1 p24 antigen detection HIV1 antibody test ( license ELISA test kit , confirmation either serum HIV1 antigen test , HIV1 antibody test do method ELISA , Western blot , plasma HIV1 RNA ) Subject must take antiretroviral medication clinical care least 4 week prior pharmacokinetic sampling , change drug , dos formulation . Subject must take either efavirenz ( EFV ) OR PI ritonavir ( RTV ) OR lopinavir/ritonavir part combination antiretroviral therapy . Note RTV dosing must `` booster '' protease inhibitor . Protease inhibitor may follow : atazanavir , darunavir , fosamprenavir , indinavir , saquinavir tipranavir . Subjects may take one fulldose PI . Subjects may take EFV addition lopinavir/ritonavir PI . Subject must take methylphenidate amphetamine/ dextroamphetamine treatment ADHD least 1 week prior enrollment . Allowable methylphenidate formulation include : immediaterelease ( Methylin , Ritalin generic , Focalin ) , sustainedrelease ( Ritalin SR , Metadate ER generic ) , biphasic ( Ritalin LA , Metadate CD , Concerta , Focalin XR ) . Allowable formulation amphetamine/ dextroamphetamine include : Adderall , Adderall XR , Dexedrine , Liquadd , Dexedrine Spansules ( generic equivalent ) . For study arm , dose maximum FDAapproved dose age allow . Subjects must able come PK sample least 2 day consecutive , uninterrupted psychiatric antiretroviral medication delivery . Parent/primary caregiver , subject &gt; 18 year emancipated minor must able willing provide sign informed consent . Assent minor subject obtain require per site procedure IRB recommendation . Female subject reproductive potential ( reach menses , reach menopause undergone hysterectomy , bilateral oophorectomy , tubal ligation ) engage sexual activity could lead pregnancy must agree avoid pregnancy entire trial consistently appropriately use least two follow contraception method : condom , diaphragm cervical cap spermicide , IUD , hormonalbased contraception . A list acceptable method find FDA Birth Control Guide ( http : //www.fda.gov/fdac/features/1997/babyguide.pdf ) . Note : `` Female subject reproductive potential '' define girl reach menarche woman postmenopausal least 24 consecutive month ( e.g . menses within precede 24 month ) , undergone sterilization procedure ( hysterectomy , bilateral oophorectomy salpingotomy ) . If female subject reproductive potential , eligible without require contraception . Inclusion Criteria HIV Uninfected Subjects Children adolescents age ≥6 &lt; 25 year entry . Subject know HIV1 infected . Note : For perinatallyexposed subject , definitive exclusion HIV1 infection nonbreastfed infant base two negative virologic test , one obtain age ≥1 month one ≥4 month , two negative HIV1 antibody test separate specimen obtain age ≥6 month . Per current CDC guideline , uninfected subject ≥13 year screen HIV1 . A documented negative HIV1 antibody screen test negative HIV1 RNA DNA PCR within past year accept fulfill criterion . Subject must take methylphenidate amphetamine/ dextroamphetamine treatment ADHD least one week prior enrollment . Allowable methylphenidate formulation include : immediaterelease ( Methylin , Ritalin generic , Focalin ) , sustainedrelease ( Methylin ER , Ritalin SR , Metadate ER generic ) , biphasic ( Ritalin LA , Metadate CD , Concerta Focalin XR . Allowable formulation amphetamine/ dextroamphetamine include : Adderall , Adderall XR , Dexedrine , Liquadd , Dexedrine Spansules ( generic equivalent ) . For arm , dose maximum FDAapproved dose age allow . Subjects must able come PK sample least 2 day consecutive , uninterrupted psychiatric medication delivery . Parent/primary caregiver , subject &gt; 18 year emancipated minor must able willing provide sign informed consent . Assent minor subject obtain require per site procedure IRB recommendation . Female subject child bear potential ( reach menses , reach menopause undergone hysterectomy , bilateral oophorectomy , tubal ligation ) engage sexual activity could lead pregnancy must agree avoid pregnancy entire trial consistently appropriately use least two follow contraception method : condom , diaphragm cervical cap spermicide , IUD , hormonalbased contraception . A list acceptable method find FDA Birth Control Guide ( http : //www.fda.gov/fdac/features/1997/babyguide.pdf ) . Note : `` Female subject child bear potential '' define girl reach menarche woman postmenopausal least 24 consecutive month ( e.g . menses within precede 24 month ) , undergone sterilization procedure ( hysterectomy , bilateral oophorectomy salpingotomy ) . If female subject child bear potential , eligible without require contraception . Exclusion Criteria All Study Subjects A positive urine test screening use follow disallow drug : methamphetamine ; methadone , barbiturates ; benzodiazepine ; opiates ; phencyclidine ; propoxyphene . Note : If propoxyphene part routine screen panel site , require . If propoxyphene part routine screen panel site , result record appropriate CRF . Chemotherapy malignancy within three month prior study screen . Pregnancy breastfeed infant . Any clinically significant disease ( HIV1 infection ) clinically significant finding screen medical history physical examination , investigator 's opinion , would compromise outcome study . Study drug prescribe FDArecommended maximum dose age . Known demonstrated hypersensitivity intolerance Dextromethorphan . Subjects take disallowed medication . For HIV1 Infected Subjects Only : Presence active CDC Stage C ( per 1994 Revised Classification System Human Immunodeficiency Virus Infection Children Less Than 13 Years Age , 1993 Revised Classification System HIV Infection Among Adolescents Adults ) opportunistic infection serious bacterial infection require therapy within two week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ADHD</keyword>
	<keyword>HIV</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>